SCHEDULE: Lincoln Alternative Strategies Discloses 18.92% Stake in Jaguar Health

Lincoln Alternative Strategies LLC has reported a significant 18.92% beneficial ownership stake in Jaguar Health, Inc. common stock.

Summary

• Lincoln Alternative Strategies LLC has filed a Schedule 13G, indicating beneficial ownership of 600,000 shares of Jaguar Health, Inc. common stock.
• This represents an 18.92% stake in the company, based on 3,171,566 shares outstanding as of August 28, 2025.
• The reporting person holds sole voting power and sole dispositive power over all 600,000 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake (18.92%) by Lincoln Alternative Strategies LLC is generally viewed positively as it suggests confidence in Jaguar Health, Inc. by a sophisticated investor. The certification that the stake is not for control purposes reduces immediate uncertainty regarding potential activist pressure.

Positives

• A significant institutional investor, Lincoln Alternative Strategies LLC, has taken an 18.92% stake in Jaguar Health, Inc., potentially signaling confidence in the company's future prospects.
• The investor holds sole voting and dispositive power over its shares, indicating direct control over its investment decisions without shared influence.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Jaguar Health, Inc. or Lincoln Alternative Strategies LLC regarding future performance or strategic direction.

Management Comments

• The filing includes a certification from Lincoln Alternative Strategies LLC that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This Schedule 13G filing indicates a significant stake taken by an alternative strategies firm in a biotechnology company. Such investments can reflect a belief in the long-term potential of the company's pipeline or market position within the pharmaceutical sector, especially given the capital-intensive nature of drug development.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership exceeding 5% by an institutional investor, as required by SEC regulations.
• It does not contain information for direct comparison to industry-specific operational or financial benchmarks of other companies or projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding an 18.92% stake could be perceived positively, potentially increasing investor confidence and market liquidity.
• Management: The certification that the stake is not for control purposes suggests that management can continue to execute its current strategy without immediate pressure from this specific investor to change direction.

Key Dates

Recommendation

The filing indicates a substantial 18.92% beneficial ownership by Lincoln Alternative Strategies LLC in Jaguar Health, Inc. While this signals institutional confidence, a Schedule 13G primarily discloses ownership and does not provide operational or financial performance details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future developments, including the company's financial performance and strategic initiatives, to assess the long-term implications of this significant stake.

Keywords

Jaguar Health, Lincoln Alternative Strategies, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals